Telomir Pharmaceuticals, Inc.
Pharmaceutical Preparations · MIAMI · FL
Moderate confidence (50%)
Updated Oct 14, 2026, 12:03 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Telomir Pharmaceuticals, Inc. received a delisting notice from its exchange (Jan 8, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Telomir Pharmaceuticals, Inc. received a delisting notice from its exchange
Jan 8, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2025, Telomir Pharmaceuticals, Inc. (the Company ) submitted its preliminary proxy statement on Schedule 14A to the Securities and Exchange Commission (the SEC ) in connection with its annual meeting of shareholders. At that time, the Company had planned to hold its annual meeting of shareholders on December 30, 2025, subject to completion of the SEC review process. The preliminary proxy statement remains under review by the SEC. On January 8, 2026, the Company receiv…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker TELO on Nasdaq.
- SEC CIK
- 0001971532
- Website
- —
- —
- Headquarters
- MIAMI, FL
- Also known as
- —
- Legal entities
- Telomir Pharmaceuticals, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
Telomir Pharmaceuticals, Inc. — Pharmaceutical Preparations (SIC 2834) — MIAMI, FL
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2025, Telomir Pharmaceuticals, Inc. (the Company ) submitted its preliminary proxy statement on Schedule 14A to the Securities and Exchange Commission (the SEC ) in connection with its annual meeting of shareholders. At that time, the Company had planned to hold its annual meeting of shareholders on December 30, 2025, subject to completion of the SEC review process. The preliminary proxy statement remains under review by the SEC. On January 8, 2026, the Company receiv…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:32 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:12 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:54 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.